Analgesics
Antiandrogens
Antihistamines
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin DVitamin D (more..)
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta

All Studies   Meta Analysis       

COVID-19 severity appears to be reduced in spring/summer

Sposato et al., Epidemiol Prev., doi:10.19191/EP23.1.A503.016
Mar 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020, now with p < 0.00000000001 from 125 studies, recognized in 9 countries.
No treatment is 100% effective. Protocols combine treatments.
5,300+ studies for 116 treatments. c19early.org
Retrospective 8,221 COVID+ patients in Italy, showing significantly lower ICU admission and CPAP/NIV use in the spring/summer compared to the winter. There was no significant difference in viral load. Vitamin D levels were higher and CRP was lower in the spring/summer.
Sposato et al., 27 Mar 2023, retrospective, Italy, peer-reviewed, 13 authors.
This PaperVitamin DAll
DOI record: { "DOI": "10.19191/EP23.1.A503.016", "ISSN": "1120-9763, 2385-1937", "URL": "https://doi.org/10.19191/EP23.1.A503.016", "abstract": "BACKGROUND: because of different human behaviours, SARS-CoV-2 spread may be lower in spring/summer. On the contrary, it is not clearly known whether the clinical course/severity of hospitalized patients infected by SARS-CoV-2 can be different in the various seasons.. Objectives: to understand whether there were differences in severity of COVID-19 in patients who had contracted the infection in winter versus those infected in spring/summer. DESIGN: observational retrospective cohort study. SETTING AND PARTICIPANTS: from the administrative database of the SARS-CoV-2 surveillance system and that of hospital discharge, a cohort of patients (8,221, 653 of which were hospitalized) who tested positive to the RT-PCR test for SARS-CoV-2 between 01.12.2020 and 31.07.2021 in the Grosseto province (Tuscany Region, Central Italy) was selected and analysed. MAIN OUTCOME MEASURES: hospitalization rate and length, continuous positive airway pressure (CPAP) or non-invasive ventilation (NIV) use, Intensive Care Unite (ICU) admissions, intra-hospital mortality and PaO2/FiO2 values were measured and compared between subjects infected in winter and those who developed COVID-19 in spring/summer. Viral load (cycle threshold, Ct), vitamin D, serum ferritin, IL-6, procalcitonin, D-dimer, and C-reactive protein measured in the two periods were also compared. RESULTS: in the considered months, the hospitalization rate among 8,221 patients with COVID-19 was 8%: 370 (8.5%) individuals were hospitalized in winter and 283 (7,3%; p=0.31) in spring/summer; 62 (16.8%), 88 (23.8%), and 63 (17%) in winter and 28 (9.9%), 40 (14.1%), and 36 (12.7%) in spring/summer were admitted in ICU (p=0.01), used CPAP/NIV (p=0.002) and died (p=0.13), respectively. Hospitalization days were 14.5±11.6 in winter and 10.3±8.84 in spring/summer (p=0.001), while minimum PaO2/FiO2, measured during hospital stays was 123.2±38.6 in spring/summer and 112.6±40.8 in winter (p=0.054). Multivariate analysis (adjusted for all confounding factors) also confirmed reduced risks of having ICU admissions (0.53; 95%CI 0.32;0.88; p=0.01) and of using CPAP/NIV (0.48; 95%CI 0.32;0.75; p=0.001) in spring/summer when compared to winter. Hospitalization days and minimum PaO2/FiO2 were also lower in spring/summer (β= -3.9; 95%CI -5.5;-2.2; p=0.001) and winter (β= -17; 95%CI -0.93;35; p=0.06), respectively. The adjusted hazard ratio of mortality in winter, obtained with a Cox model, was higher of about 38% compared to spring/summer. No Ct values (viral load) differences were found either in winter (19.45±6.18) or spring/summer (20.3±6.7; p=0.343). IL-6, ferritin, procalcitonin, D-dimer were similar. Conversely, CRP was lower whereas vitamin D was higher in the warmer seasons. CONCLUSIONS: COVID-19 may be less severe during spring/summer in hospitalized patients. This does not seem to be influenced by different SARS-CoV-2 viral load in the different periods considered. C-reactive protein was found to be lower whereas vitamin D higher in the warmer months. It can be hypothesized that higher levels of vitamin D in spring/summer, compared to winter, may be associated to a positive modulation of COVID-19 induced inflammation with a possible disease severity reduction during spring/summer.", "author": [ { "family": "Sposato", "given": "Bruno" }, { "family": "Serafini", "given": "Andrea" }, { "family": "Simoncini", "given": "Enrico" }, { "family": "Croci", "given": "Leonardo" }, { "family": "Guidoni", "given": "Chiara" }, { "family": "Scalese", "given": "Marco" }, { "family": "Baratta", "given": "Pasquale" }, { "family": "Cresti", "given": "Alberto" }, { "family": "Lacerenza", "given": "Leonardo Gianluca" }, { "family": "Lena", "given": "Fabio" }, { "family": "Nencioni", "given": "Cesira" }, { "family": "Spargi", "given": "Genni" }, { "family": "Perrella", "given": "Antonio" } ], "container-title": "Epidemiologia & Prevenzione", "container-title-short": "E&P", "issue": "1-2", "issued": { "date-parts": [ [ 2023, 3 ] ] }, "journalAbbreviation": "E&P", "keyword": "COVID-19; SARS-CoV-2; viral load; severity; inflammation; season; vitamin D", "medium": "JB", "publisher": "Inferenze scarl", "publisher-place": "IT", "title": "In primavera/estate la gravità del COVID-19 appare ridotta", "type": "article-journal", "volume": "47" }
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit